---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Definition and etiology"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Definition and etiology. Topics: Definition: chronic immune-mediated skin disease with distinct subtypes, Definition: chronic papulosquamous disease presenting at any age, Case definition in the Global Burden of Disease Study 2021, Plaque psoriasis as the most common variant, and 6 further topics. 10 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition: chronic immune-mediated skin disease with distinct subtypes

> “Psoriasis is a chronic immune-mediated inflammatory skin disease with multiple phenotypically distinct subtypes eg plaque, flexural, guttate, pustular or erythrodermic.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-2"></a>

### Definition: chronic papulosquamous disease presenting at any age

> “Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.1-3"></a>

### Case definition in the Global Burden of Disease Study 2021

> “In the GBD 2021, psoriasis was defined as a common, chronic, and recurrent inflammatory skin disease characterized by abnormal epidermal keratinization and hyperproliferation.”
> “Psoriasis diagnosis was based on the international Classification of diseases 10 (ICD-10: L40 and L41).”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.1-4"></a>

### Plaque psoriasis as the most common variant

> “Plaque psoriasis is the most common variant of psoriasis.”

Source: [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/)

<a id="topic-2.2.1.1-5"></a>

### Etiology of chronic plaque psoriasis: HLA-C risk allele and environmental triggers

> “Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption.”

Source: [Griffiths et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33812489/)

<a id="topic-2.2.1.1-6"></a>

### Heritability: population-based twin study of 10,725 twin pairs

> “Data on psoriasis in 10 725 twin pairs, aged 20-71 years, from the Danish Twin Registry was collected via a questionnaire survey.”
> “Genetic factors explained 68% (60-75%) of the variation in the susceptibility to psoriasis, whereas the rest of the variation was explained by nonshared environmental factors.”

Source: [Lønnberg et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23574549/)

<a id="topic-2.2.1.1-7"></a>

### Heritability range and susceptibility loci from genome-wide association studies

> “This was demonstrated by twin, family-based and large-scale population-level studies, with heritability estimated to be 60–90%.”
> “More than 60 susceptibility loci have now been identified using genome-wide association studies.”
> “Many of the candidate causal genes are involved in antigen presentation (HLA-C and ERAP1), NF-kappa B signalling (TNIP1), type 1 interferon pathway (RNF113 and IFIH1), interleukin (IL)-23/Th17 axis (IL23R, IL12B and TYK2) and skin barrier function (LCE3).”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-8"></a>

### Major histocompatibility complex share of detectable heritability

> “In all populations, the strongest psoriasis association signals map to the major histocompatibility complex (MHC), comprising approximately 40% of the detectable heritability of psoriasis.”

Source: [Stuart et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8682265/)

<a id="topic-2.2.1.1-9"></a>

### Environmental triggers: obesity, stress, medications, and smoking

> “Environmental triggers have been known to exacerbate psoriasis such as obesity, stress, beta-blockers, smoking and lithium.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.1-10"></a>

### Body mass index as a causal risk factor: mendelian randomization

> “Overall, a 1 kg/m2 increase in BMI was associated with 4% higher odds of psoriasis (meta-analysis odds ratio [OR] = 1.04; 95% CI 1.03–1.04;”
> “MR analyses provided evidence that higher BMI causally increases the odds of psoriasis (by 9% per 1 unit increase in BMI; OR = 1.09 (1.06–1.12) per 1 kg/m2”

Source: [Budu-Aggrey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6354959/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
